Purchasers of Allergan Plc’s Namenda asked a federal judge to approve a $750 million settlement of claims that the drugmaker conspired to keep generic versions of the Alzheimer’s medication off the market.

Bausch Health settled a class action lawsuit for $1.21 billion related to a drop in the drugmaker’s shares during 2013-2015.

Allergan will pay $750 million to settle a class action lawsuit from a group of direct purchasers of the Alzheimer’s disease therapy Namenda in a resolution to the litigation that was set to face trial.

Gilead Sciences has been accused of withholding safer formulations of its HIV drugs in order to maximize profits on those medications that had already been approved, such as Truvada.